The impressive efficacy of ACT-TIL therapy in metastatic melanoma is highlighted not only by higher ORRs (approximately 50%) but also durable and complete response (CR) rates (13%), which exceed those of some immunotherapies, such as checkpoint-blockade agents in TNBC and HER2-positive BC [123,124,125,126]. The gene discussed is ERBB2; the disease is breast cancer.